Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21
Claudia Giordano, Marco Picardi, Novella Pugliese, Annamaria Vincenzi, Davide Pio Abagnale, Laura De Fazio, Maria Luisa Giannattasio, Carmina Fatigati, Mauro Ciriello, Alessia Salemme, Giada Muccioli Casadei, Elena Vigliar, Massimo Mascolo, Giancarlo Troncone, Fabrizio Pane
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2023.
All research outputs
#15,117,059
of 26,171,302 outputs
Outputs from Frontiers in oncology
#4,009
of 22,919 outputs
Outputs of similar age
#211,262
of 513,157 outputs
Outputs of similar age from Frontiers in oncology
#208
of 1,484 outputs
Altmetric has tracked 26,171,302 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,919 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 513,157 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.
We're also able to compare this research output to 1,484 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.